{"title":"他汀类药物:增加2型糖尿病的风险。","authors":"","doi":"","DOIUrl":null,"url":null,"abstract":"<p><p>Five meta-analyses of double-blind randomised comparative clinical trials have shown a small but statistically significant increase in the risk of type 2 diabetes in statin users. The relative risk was about 1.1. One add- itional case of diabetes occurred for approximately every 255 patients treated with a statin for 4 years. The risk is dose-dependent. It was observed with all the statins studied, including pravastatin, simvastatin, atorvastatin and rosuvastatin. In practice, the risk of diabetes is not a reason for choosing one statin rather than another. When statin ther- apy is justified, pravastatin and simva- statin remain the statins of choice.</p>","PeriodicalId":35983,"journal":{"name":"Prescrire International","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2017-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Statins: increased risk of type 2 diabetes.\",\"authors\":\"\",\"doi\":\"\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Five meta-analyses of double-blind randomised comparative clinical trials have shown a small but statistically significant increase in the risk of type 2 diabetes in statin users. The relative risk was about 1.1. One add- itional case of diabetes occurred for approximately every 255 patients treated with a statin for 4 years. The risk is dose-dependent. It was observed with all the statins studied, including pravastatin, simvastatin, atorvastatin and rosuvastatin. In practice, the risk of diabetes is not a reason for choosing one statin rather than another. When statin ther- apy is justified, pravastatin and simva- statin remain the statins of choice.</p>\",\"PeriodicalId\":35983,\"journal\":{\"name\":\"Prescrire International\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2017-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Prescrire International\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"Medicine\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Prescrire International","FirstCategoryId":"1085","ListUrlMain":"","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"Medicine","Score":null,"Total":0}
Five meta-analyses of double-blind randomised comparative clinical trials have shown a small but statistically significant increase in the risk of type 2 diabetes in statin users. The relative risk was about 1.1. One add- itional case of diabetes occurred for approximately every 255 patients treated with a statin for 4 years. The risk is dose-dependent. It was observed with all the statins studied, including pravastatin, simvastatin, atorvastatin and rosuvastatin. In practice, the risk of diabetes is not a reason for choosing one statin rather than another. When statin ther- apy is justified, pravastatin and simva- statin remain the statins of choice.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
